r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

JK

Jason A. Keyes

Insider · Chief Financial Officer · BLSM

Jason A. Keyes files insider transactions with the SEC as a chief financial officer of BlossomHill Therapeutics. We hold 1 disclosed purchase or sale filed since 14 July 2016, 1 of them in the last 90 days.

  • Files for 5 companiesBLSM, ACTU, EQ, SESN and 1 more
  • Disclosed buys and sells1 in all, 1 in the last 90 days
  • Last disclosure10 August 2026

Positions held

5 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 6 August 2026 — 10 August 2026Chief Financial Officer · BlossomHill Therapeutics 2 Form 4 lines · source: SEC Form 4
  • Filed 12 August 2024 — 21 May 2026Director · Actuate Therapeutics 3 Form 4 lines · source: SEC Form 4
  • Filed 13 February 2019 — 14 February 2025Chief Financial Officer · Equillium 46 Form 4 lines · source: SEC Form 4
  • Filed 24 February 2020 — 22 June 2022Director · Sesen Bio 5 Form 4 lines · source: SEC Form 4
  • Filed 12 July 2016 — 13 October 2017EVP, Chief Financial Officer · Orexigen Therapeutics 9 Form 4 lines · source: SEC Form 4

Every transaction

65 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
65 of 65 shown
10 Aug 202610 Aug 2026SEC Form 40 dbought on the open marketBlossomHill Therapeutics700 sharesup +37.6%up +37.6%
6 Aug 202610 Aug 2026SEC Form 44 dwas grantednot a tradeBlossomHill Therapeuticsderivative56,746 shares—up +37.6%
21 May 202622 May 2026SEC Form 41 dwas grantednot a tradeActuate Therapeuticsderivative15,000 sharesdown −47.9%down −47.1%
22 May 202523 May 2025SEC Form 41 dwas grantednot a tradeActuate Therapeuticsderivative15,000 sharesdown −87.5%down −87.8%
14 Feb 202519 Feb 2025SEC Form 45 dwas grantednot a tradeEquilliumderivative70,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dreturned to the issuernot a tradeEquilliumderivative70,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dwas grantednot a tradeEquilliumderivative90,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dreturned to the issuernot a tradeEquilliumderivative90,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dwas grantednot a tradeEquilliumderivative100,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dreturned to the issuernot a tradeEquilliumderivative100,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dwas grantednot a tradeEquilliumderivative125,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dreturned to the issuernot a tradeEquilliumderivative125,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dwas grantednot a tradeEquilliumderivative175,000 sharesup +172.3%up +184.4%
14 Feb 202519 Feb 2025SEC Form 45 dreturned to the issuernot a tradeEquilliumderivative175,000 sharesup +172.3%up +184.4%
23 Jan 202524 Jan 2025SEC Form 41 dsold on the open marketEquillium10,000 sharesup +282.1%up +276.5%
2 Jan 20256 Jan 2025SEC Form 44 dwas grantednot a tradeEquilliumderivative175,000 sharesup +232.5%up +232.5%
10 Dec 20246 Jan 2025SEC Form 427 dwas grantednot a tradeEquillium15,000 sharesup +265.7%up +232.5%
14 Nov 202415 Nov 2024SEC Form 41 dsold on the open marketEquillium10,000 sharesup +276.5%up +260.6%
26 Sep 202427 Sep 2024SEC Form 41 dsold on the open marketEquillium10,000 sharesup +224.1%up +208.4%
12 Aug 202414 Aug 2024SEC Form 42 dwas grantednot a tradeActuate Therapeuticsderivative30,000 shares—down −86.2%
16 Jul 202418 Jul 2024SEC Form 42 dsold on the open marketEquillium10,000 sharesup +181.3%up +181.3%
2 Jan 20243 Jan 2024SEC Form 41 dwas grantednot a tradeEquilliumderivative175,000 sharesup +250.7%up +241.3%
8 Dec 20233 Jan 2024SEC Form 426 dwas grantednot a tradeEquillium8,805 sharesup +276.5%up +241.3%
9 Jun 20233 Jan 2024SEC Form 4208 dwas grantednot a tradeEquillium15,000 sharesup +287.9%up +241.3%
3 Jan 20234 Jan 2023SEC Form 41 dwas grantednot a tradeEquilliumderivative175,000 sharesup +141.5%up +116.9%
9 Dec 20224 Jan 2023SEC Form 426 dwas grantednot a tradeEquillium4,444 sharesup +82.9%up +116.9%
29 Aug 202230 Aug 2022SEC Form 41 dsold on the open marketEquillium7,000 sharesdown −10.2%down −8.2%
22 Jun 202224 Jun 2022SEC Form 42 dwas grantednot a tradeSESNSesen Bioderivative65,000 shares——
22 Jun 202224 Jun 2022SEC Form 42 dwas grantednot a tradeSESNSesen Bio40,000 shares——
6 Jun 20226 Jun 2022SEC Form 40 dsold on the open marketEquillium5,000 sharesup +2.4%up +2.4%
4 Apr 20225 Apr 2022SEC Form 41 dsold on the open marketEquillium8,000 sharesdown −21.2%down −21.5%
19 Jan 20227 Feb 2023SEC Form 4384 dwas grantednot a tradeEquilliumderivative125,000 sharesdown −33.7%up +108.1%
10 Dec 202113 Dec 2021SEC Form 43 dwas grantednot a tradeEquillium5,585 sharesdown −46.6%down −44.9%
1 Dec 20213 Dec 2021SEC Form 42 dsold on the open marketEquillium5,000 sharesdown −46.2%down −47.5%
27 Sep 202129 Sep 2021SEC Form 42 dsold on the open marketEquillium8,000 sharesdown −62.1%down −58.4%
27 Jul 202128 Jul 2021SEC Form 41 dsold on the open marketEquillium5,000 sharesdown −56.2%down −53.4%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeEquillium5,535 sharesdown −63.3%down −57.3%
26 May 202128 May 2021SEC Form 42 dsold on the open marketEquillium5,000 sharesdown −60.9%down −61.0%
26 May 202128 May 2021SEC Form 42 dsold on the open marketEquillium5,000 sharesdown −60.9%down −61.0%
3 May 20215 May 2021SEC Form 42 dwas grantednot a tradeSESNSesen Bioderivative92,500 shares——
4 Jan 20216 Jan 2021SEC Form 42 dwas grantednot a tradeEquilliumderivative100,000 sharesdown −49.1%down −49.3%
23 Dec 202028 Dec 2020SEC Form 45 dsold on the open marketEquillium8,000 sharesdown −45.5%down −41.3%
10 Dec 202011 Dec 2020SEC Form 41 dacquired or disposed of, othernot a tradeEquillium5,362 sharesdown −46.2%down −47.3%
10 Jun 202012 Jun 2020SEC Form 42 dacquired or disposed of, othernot a tradeEquillium5,014 sharesdown −9.9%down −4.8%
6 May 20208 May 2020SEC Form 42 dwas grantednot a tradeSESNSesen Bioderivative59,000 shares——
22 Apr 202024 Apr 2020SEC Form 42 dreturned to the issuernot a tradeEquilliumderivative70,000 sharesup +4.5%down −10.2%
22 Apr 202024 Apr 2020SEC Form 42 dwas grantednot a tradeEquilliumderivative70,000 sharesup +4.5%down −10.2%
22 Apr 202024 Apr 2020SEC Form 42 dreturned to the issuernot a tradeEquilliumderivative90,000 sharesup +4.5%down −10.2%
22 Apr 202024 Apr 2020SEC Form 42 dwas grantednot a tradeEquilliumderivative90,000 sharesup +4.5%down −10.2%
24 Feb 202026 Feb 2020SEC Form 42 dwas grantednot a tradeSESNSesen Bioderivative118,000 shares——
18 Feb 202019 Feb 2020SEC Form 41 dsold on the open marketEquillium5,000 sharesdown −49.4%down −49.1%
21 Jan 202022 Jan 2020SEC Form 41 dsold on the open marketEquillium5,000 sharesdown −42.0%down −38.2%
10 Dec 201912 Dec 2019SEC Form 42 dwas grantednot a tradeEquilliumderivative90,000 sharesdown −46.1%down −46.1%
3 Sep 20194 Sep 2019SEC Form 41 dsold on the open marketEquillium5,000 sharesdown −28.3%down −29.7%
1 Aug 20195 Aug 2019SEC Form 44 dsold on the open marketEquillium5,000 sharesdown −35.2%down −36.0%
13 Feb 201915 Feb 2019SEC Form 42 dwas grantednot a tradeEquilliumderivative70,000 sharesdown −64.2%down −60.7%
13 Oct 201717 Oct 2017SEC Form 44 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative69,600 shares——
31 May 20172 Jun 2017SEC Form 42 dwas grantednot a tradeOREXOrexigen Therapeutics557 shares——
3 Feb 20177 Feb 2017SEC Form 44 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative87,000 shares——
3 Feb 20177 Feb 2017SEC Form 44 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative43,500 shares——
30 Nov 20162 Dec 2016SEC Form 42 dwas grantednot a tradeOREXOrexigen Therapeutics291 shares——
12 Jul 201614 Jul 2016SEC Form 42 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative131,250 shares——
12 Jul 201614 Jul 2016SEC Form 42 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative26,250 shares——
12 Jul 201614 Jul 2016SEC Form 42 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative78,750 shares——
12 Jul 201614 Jul 2016SEC Form 42 dwas grantednot a tradeOREXOrexigen Therapeuticsderivative15,750 shares——

Both percentages are the stock’s move, not Jason A. Keyes’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 49 of the 65 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.